A new study has found comprehensive evidence that “weight-loss” GLP-1 receptor agonists such as semaglutide are effective in tackling the biological drivers of Alzheimer’s disease. The study, published in the journal Molecular and Cellular Neuroscience, examined 30 preclinical studies investigating the effects of four GLP-1 receptor agonists—liraglutide; semaglutide; exenatide; and dulaglutide—on Alzheimer’s disease pathology.
This article was originally published on MedicalXpress.com
Whether you jog to keep fit or compete in marathons, the physically demanding sport of running can deplete the body of essential nutrients. During a race like a half-marathon, a runner’s metabolism — or ability […]
In this article, we will introduce you to 12 incredibly effective foot massage techniques that will leave you feeling rejuvenated and relaxed. Foot massages aren’t just a luxury; they provide numerous health benefits, such as […]
Effective communication is the foundation of any strong, healthy relationship. This article will explore the key elements required to build better communication between partners. We’ll cover the importance of active listening, using empathy and understanding […]
© 2025 SimplyWell.ca